Literature DB >> 22127594

General insufficiency of the classical CDC-based crossmatch to detect donor-specific anti-HLA antibodies leading to invalid results under recipients' medical treatment or underlying diseases.

G Schlaf1, C Mauz-Körholz, U Ott, S Leike, W Altermann.   

Abstract

Antibodies directed against HLA antigens of a given donor represent the most prominent cause for hyper-acute and acute rejections. In order to select recipients without donor-specific antibodies the complement-dependent cytotoxicity (CDC-) crossmatch as the standard procedure was established. As a functional assay it strongly depends on the availability of isolated donor lymphocytes and in particular on their vitality. However, due to several diseases or pharmacological treatment of a given recipient unexpected "false-positive" results of the CDC-crossmatch may arise. We here present three groups of patients which demonstrate the limits of the conventional crossmatch. 1) Kidney recipients before living donations exhibited positive CDC-reactions due to their conditioning using the therapeutical anti-CD20 mAb Rituximab (n=7), routinely used to deplete B-cells, or the anti-CD25 mAb basiliximab (n=2) to inhibit the proliferation of activated T-cells. 2) Recipients suffering from various leukaemias (n=5) exhibited "positive" CDC-crossmatches using PBL of the donors, although formerly these patients had never shown anti-HLA antibodies. Instead of donor-specific allo-antibodies, cytostatic agents such as 6-mercaptopurine led to an unspecific cell death. 3) Patients projected for post mortem or living kidney donations (n=44) exhibited "positive" CDC-crossmatch results which were not in accordance with their former antibody status and, partially, with high degrees of HLA-matching. These implausible results were due to underlying auto-immune diseases, mainly of the systemic immune complex type III such as lupus erythematosus, mainly leading to false-positive B-cell crossmatches by immune complexes binding to Fcγ-receptors. In all these 58 cases the alternatively performed ELISA-based "Antibody Monitoring System" (AMS-) crossmatch assay was not artifically affected, suggesting that this assay may be comprehensively established at least for the cases described.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22127594     DOI: 10.14670/HH-27.31

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  6 in total

Review 1.  Sensitive solid-phase detection of donor-specific antibodies as an aid highly relevant to improving allograft outcomes.

Authors:  Gerald Schlaf; Beatrix Pollok-Kopp; Wolfgang W Altermann
Journal:  Mol Diagn Ther       Date:  2014-04       Impact factor: 4.074

2.  Identification of a recurrent pattern of false-positivity by Luminex HLA MHC class I single antigen bead testing.

Authors:  Christina L Dean; Scott M Krummey; Howard M Gebel; Robert A Bray; Harold C Sullivan
Journal:  Hum Immunol       Date:  2020-01-06       Impact factor: 2.850

3.  Preemptive CD20+ B cell Depletion Attenuates Cardiac Allograft Vasculopathy in CD154-Treated Monkeys.

Authors:  Agnes M Azimzadeh; Tianshu Zhang; Guosheng Wu; Shahrooz S Kelishadi; Tiffany Stoddard; Natalie OʼNeill; Bao-Ngoc Nguyen; Emily Welty; Christopher Avon; Mitch Higuchi; Stuart L Mitchell; Alena Hershfeld; Xiang-Fei Cheng; Anthony Kronfli; Elana Rybak; Lars Burdorf; Richard N Pierson
Journal:  Transplantation       Date:  2017-01       Impact factor: 4.939

4.  Solid phase-based cross-matching as solution for kidney allograft recipients pretreated with therapeutic antibodies.

Authors:  Gerald Schlaf; Susanne Apel; Anja Wahle; Wolfgang W Altermann
Journal:  Biomed Res Int       Date:  2015-01-15       Impact factor: 3.411

Review 5.  Human leukocyte antigen typing and crossmatch: A comprehensive review.

Authors:  Mohammed Mahdi Althaf; Mohsen El Kossi; Jon Kim Jin; Ajay Sharma; Ahmed Mostafa Halawa
Journal:  World J Transplant       Date:  2017-12-24

6.  ELISA-Based Crossmatching Allowing the Detection of Emerging Donor-Specific Anti-HLA Antibodies through the Use of Stored Donors' Cell Lysates.

Authors:  G Schlaf; K Stöhr; A Rothhoff; W Altermann
Journal:  Case Rep Transplant       Date:  2015-11-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.